Concepedia

Publication | Closed Access

Prospective Analysis in Patients With HAE Under Prophylaxis With Lanadelumab: A Real-life Experience

DOI

19

Citations

0

References

2020

Year

Janina Hahn, Susanne Trainotti, Marlene C. Wigand, Patrick J. Schuler, Thomas Hoffmann, Jens Greve
Journal of Drugs in Dermatology

Abstract

Lanadelumab is an effective but expensive long-term prophylaxis for HAE patients. A favorable side-effect profile has been shown. J Drugs Dermatol. 2020;19(10):978-983. doi:10.36849/JDD.2020.5269.